Akari Therapeutics (NASDAQ:AKTX) Shares Pass Below Two Hundred Day Moving Average – Should You Sell?

Akari Therapeutics PLC (NASDAQ:AKTX) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $15.38 and traded as low as $5.08. Akari Therapeutics shares last traded at $5.80, with a volume of 20,264 shares traded.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Maxim Group lowered Akari Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, April 8th. LADENBURG THALM/SH SH assumed coverage on Akari Therapeutics in a research report on Monday, January 5th. They set a “buy” rating and a $40.00 price target on the stock. HC Wainwright raised their price target on Akari Therapeutics to $27.00 and gave the stock a “buy” rating in a research report on Wednesday, April 1st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Akari Therapeutics in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Akari Therapeutics currently has an average rating of “Hold” and a consensus target price of $89.00.

Akari Therapeutics Stock Performance

The company has a 50-day simple moving average of $7.46 and a two-hundred day simple moving average of $15.20.

Akari Therapeutics (NASDAQ:AKTX) last posted its quarterly earnings results on Monday, March 30th. The biopharmaceutical company reported ($2.68) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($2.65).

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Akari Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned about 5.95% of Akari Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 5.06% of the company’s stock.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.